. A nurse is preparing to administer filgrastim 5 mcg/kg/day subcutaneous to a client who weighs 143 lb. How many mcg should the nurse administer per day? (Round the answer to the nearest whole number. Use a leading zero if it applies. Do not use a trailing zero.) _mcg

A) Hypertension: Amiodarone is not typically associated with hypertension. Instead, it is more commonly associated with hypotension.

B) Bradypnea: Amiodarone is not typically associated with bradypnea. Instead, it is more commonly associated with pulmonary toxicity, which can manifest as cough, dyspnea, and pulmonary fibrosis.

C) Fever: While fever is a possible adverse effect of amiodarone, it is not one of the most commonly observed adverse effects. Other adverse effects, such as thyroid dysfunction, pulmonary toxicity, and hepatic toxicity, are more frequently reported.

D) Bradycardia: This is the correct answer. Amiodarone is known to cause bradycardia as an adverse effect. It has a negative chronotropic effect, meaning it can slow down the heart rate. Bradycardia is one of the most commonly observed adverse effects of amiodarone and can be significant, particularly in individuals with pre-existing sinus node dysfunction or conduction abnormalities.

A) Increased urinary output: Ondansetron is a 5-HT3 receptor antagonist commonly used to prevent and treat nausea and vomiting, particularly in chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting. While increased urinary output may be indicative of improved hydration status or renal function, it is not a direct indicator of ondansetron's effectiveness in controlling nausea and vomiting. Therefore, it is not the most appropriate finding to assess the effectiveness of ondansetron.

B) Reduced dizziness: Ondansetron primarily targets nausea and vomiting by blocking serotonin receptors in the gastrointestinal tract and the chemoreceptor trigger zone. While dizziness may sometimes accompany nausea and vomiting, its reduction may not directly correlate with the effectiveness of ondansetron. Additionally, dizziness can have various causes beyond nausea and vomiting, such as orthostatic hypotension or vestibular dysfunction. Therefore, reduced dizziness alone may not reliably indicate the effectiveness of ondansetron.

C) Absence of peripheral neuropathy: Peripheral neuropathy refers to damage or dysfunction of peripheral nerves, commonly resulting in symptoms such as numbness, tingling, or weakness in the extremities. Ondansetron is not indicated for the treatment of peripheral neuropathy, and its effectiveness in controlling nausea and vomiting would not directly influence the presence or absence of peripheral neuropathy. Therefore, this finding is unrelated to the effectiveness of ondansetron in managing nausea and vomiting.

D) Decreased nausea: Ondansetron is primarily prescribed to alleviate nausea and vomiting associated with various conditions. Therefore, a decrease in nausea would indicate that ondansetron is effective in achieving its therapeutic goal. Assessing the client's level of nausea and observing a reduction in nausea symptoms after administering ondansetron is a direct and appropriate way to evaluate its effectiveness in controlling nausea and vomiting. Thus, decreased nausea is the most accurate indicator of ondansetron's effectiveness among the options provided.